Résumé
The effect of the long-acting somatostatin analogue SMS-201995 on diabetes control was assessed in 6 insulin-dependent diabetic patients (3 men and 3 women agged 19-38 years). Plasma glucose and triglyceride profiles were obtained ion 4 consecutive days, from 8:00 a.m. to 2:00 p. m. On the first 2 days the patients received their usual dose of insulin and ate at 8:00 a. m. and noon. On the third and fourth days they received 1/3 of their usual insulin dose together with 100 ug SMS-201995 injected subcutaneously. Postprandial glucose and triglyceride increases were blunted during the 360 min of observation on both day after SMS-201995 administration. The areas under the glucose-time plots fell from 23.72 ñ 12.29 (mean ñ SD) to 7.98 ñ 14.26 (P<0.05) and the areas under the triglyceride-time plots from 10.51 ñ 9.01 to -3.15 ñ 4.30 g. min.dl-1 (P<0.01). No adverse rfeactions were observed after SMS-201995 administration for 2 days. We conclude that administration of the somatostatin analogue SMS-201995 may be beneficial for insulin-dependent diabetic patients